Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
3.590
-0.310 (-7.95%)
At close: Aug 15, 2025, 4:00 PM
3.620
+0.030 (0.84%)
After-hours: Aug 15, 2025, 5:16 PM EDT
LIXT Employees
Lixte Biotechnology Holdings had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,544,476
Market Cap
16.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -2 | -50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | 3 | 300.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LIXT News
- 1 day ago - 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025 - GlobeNewsWire
- 1 day ago - 24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025 - GlobeNewsWire
- 2 days ago - 24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy - GlobeNewsWire
- 2 days ago - LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency - GlobeNewsWire
- 4 weeks ago - LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements - GlobeNewsWire
- 5 weeks ago - Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering - GlobeNewsWire
- 5 weeks ago - New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials - GlobeNewsWire
- 5 weeks ago - Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement - GlobeNewsWire